NO20055826L - HIV-prodroger spaltbare ved CD26 - Google Patents

HIV-prodroger spaltbare ved CD26

Info

Publication number: NO20055826L
Authority: NO; Norway
Prior art keywords: prodrugs; acid; allyl; present; dipeptidyl
Prior art date: 2003-05-08

Application number

NO20055826A

Other languages

English (en)

Norwegian (no)

Other versions

NO20055826D0 (no

Inventor

Jan Mr Balzarini

Piet Tom Bert Paul Wigerinck

Herman Augustinus De Kock

Original Assignee

Tibotec Pharm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-08

Filing date

2005-12-08

Publication date

2006-02-08

2005-12-08 Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd

2005-12-08 Publication of NO20055826D0 publication Critical patent/NO20055826D0/no

2006-02-08 Publication of NO20055826L publication Critical patent/NO20055826L/no

Links

239000000651 prodrug Substances 0.000 title abstract 5
229940002612 prodrug Drugs 0.000 title abstract 5
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 title abstract 3
101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 title abstract 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 3
IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical group OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 abstract 2
DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 abstract 2
FJLFXMJCHNQICR-RXMQYKEDSA-N (2r)-1,2-dihydroxypyrrolidine-2-carboxylic acid Chemical group ON1CCC[C@@]1(O)C(O)=O FJLFXMJCHNQICR-RXMQYKEDSA-N 0.000 abstract 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical group OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 abstract 1
108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 abstract 1
102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 abstract 1
101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 abstract 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
239000004473 Threonine Substances 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
235000004279 alanine Nutrition 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000005336 allyloxy group Chemical group 0.000 abstract 1
229940024606 amino acid Drugs 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004104 aryloxy group Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Chemical group OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
229960002591 hydroxyproline Drugs 0.000 abstract 1
229960000310 isoleucine Drugs 0.000 abstract 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
DJIWKBNZEOPEAM-JEDNCBNOSA-N piperidine-2-carboxylic acid;(2s)-piperidine-2-carboxylic acid Chemical group OC(=O)C1CCCCN1.OC(=O)[C@@H]1CCCCN1 DJIWKBNZEOPEAM-JEDNCBNOSA-N 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229930195734 saturated hydrocarbon Natural products 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Chemical group ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)

NO20055826A 2003-05-08 2005-12-08 HIV-prodroger spaltbare ved CD26 NO20055826L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0310593.9A GB0310593D0 (en)	2003-05-08	2003-05-08	Peptidic prodrugs
PCT/EP2004/050753 WO2004099135A2 (en)	2003-05-08	2004-05-10	Hiv prodrugs cleavable by cd26

Publications (2)

Publication Number	Publication Date
NO20055826D0 NO20055826D0 (no)	2005-12-08
NO20055826L true NO20055826L (no)	2006-02-08

Family

ID=9957688

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055826A NO20055826L (no)	2003-05-08	2005-12-08	HIV-prodroger spaltbare ved CD26

Country Status (22)

Country	Link
US (2)	US20080214648A1 (pt)
EP (2)	EP1620130A1 (pt)
JP (2)	JP2006525235A (pt)
KR (1)	KR20060008300A (pt)
CN (1)	CN1784244A (pt)
AP (1)	AP2005003465A0 (pt)
AT (1)	ATE375172T1 (pt)
AU (2)	AU2004236371B2 (pt)
BR (1)	BRPI0410158A (pt)
CA (2)	CA2517338A1 (pt)
DE (1)	DE602004009435T2 (pt)
DK (1)	DK1624897T3 (pt)
EA (1)	EA009727B1 (pt)
ES (1)	ES2295879T3 (pt)
GB (1)	GB0310593D0 (pt)
MX (1)	MXPA05012019A (pt)
NO (1)	NO20055826L (pt)
NZ (1)	NZ543946A (pt)
PT (1)	PT1624897E (pt)
UA (1)	UA82221C2 (pt)
WO (2)	WO2004098644A1 (pt)
ZA (1)	ZA200509940B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005319578A1 (en)	2004-11-24	2006-06-29	Neopro Labs, Llc	Methods and compositions for treating conditions
ES2381118T3 (es) *	2004-12-23	2012-05-23	Campina Nederland Holding B.V.	Hidrolizado de proteínas enriquecido en péptidos de inhibición de DPP-IV y su uso
JP2009517464A (ja)	2005-11-30	2009-04-30	カンピーナネーダーランドホールディングビー．ブイ．	グルカゴン様ペプチド１の活性を増強するタンパク質加水分解物の使用
EP2015765A4 (en)	2006-03-28	2011-11-23	Neopro Labs Llc	METHODS AND COMPOSITIONS FOR TREATING CONDITIONS
CA2683288A1 (en)	2007-05-17	2008-11-27	Neopro Labs, Llc	Crystalline and amorphous forms of peptide
EP2217701B9 (en) *	2007-10-30	2015-02-18	Indiana University Research and Technology Corporation	Glucagon antagonists
EP2249853A4 (en)	2008-01-30	2012-12-26	Univ Indiana Res & Tech Corp	ESTER BASED PEPTIDE PRODRUGS
EP2276479B1 (en)	2008-04-15	2014-07-02	SineVir Therapeutics LLC	Prodrugs of neuraminidase inhibitors
AU2009290531B2 (en) *	2008-09-12	2014-08-21	Cadila Pharmaceuticals Ltd.	Novel dipeptidyl peptidase (DP-IV) compounds
CN103396473A (zh)	2008-11-04	2013-11-20	安科治疗公司	Cxcr4受体化合物
RU2411248C2 (ru) *	2008-11-13	2011-02-10	Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН)	Средство, обладающее антипсихотической активностью
AU2009327418A1 (en)	2008-12-19	2010-06-24	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
KR20110114568A (ko) *	2008-12-19	2011-10-19	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	디펩티드 링크된 약효 물질
WO2011061590A1 (en)	2009-11-17	2011-05-26	Hetero Research Foundation	Novel carboxamide derivatives as hiv inhibitors
EP2566494B1 (en) *	2010-02-26	2017-11-29	Acer Therapeutics, Inc.	Cxcr4 receptor compounds
US8946147B2 (en)	2010-06-24	2015-02-03	Indiana University Research And Technology Corporation	Amide-based insulin prodrugs
US10426740B1 (en)	2010-08-18	2019-10-01	Avm Biotechnology, Llc	Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
DK3066091T3 (da) *	2013-11-05	2019-07-15	Astrazeneca Ab	Nmda-antagonist-prodrugs
WO2016039403A1 (ja) *	2014-09-11	2016-03-17	塩野義製薬株式会社	持続性ｈｉｖプロテアーゼ阻害剤
EP3197912B1 (en) *	2014-09-24	2023-01-04	Indiana University Research & Technology Corporation	Lipidated amide-based insulin prodrugs
AU2016270597B2 (en) *	2015-05-29	2022-05-26	Arrowhead Pharmaceuticals, Inc.	Biologically cleavable tetrapeptide linking agents
CA3054443A1 (en)	2017-04-01	2018-10-14	Avm Biotechnology, Llc	Replacement of cytotoxic preconditioning before cellular immunotherapy
WO2019002945A2 (en) *	2017-06-29	2019-01-03	UREKA, Sarl	PEPTIDE PRO-MEDICINE HAVING IMPROVED PHARMACEUTICAL PROPERTIES
EP3488851A1 (en)	2018-10-03	2019-05-29	AVM Biotechnology, LLC	Immunoablative therapies
CN111233955B (zh) *	2020-02-28	2022-06-10	南京缘聚医药科技有限公司	一类噻唑酮甲酰胞嘧啶衍生物及其药物用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL55431A (en) *	1978-08-24	1982-07-30	Yeda Res & Dev	Anthracycline type antibiotics,their preparation and pharmaceutical compositions comprising them
WO1987007276A1 (fr) *	1986-05-30	1987-12-03	Fuji Kagaku Kogyo Kabushiki Kaisha	Nouveaux composes de 5-fluorouridine et procede de preparation
US5627035A (en) *	1990-08-22	1997-05-06	Syntello Vaccine Development Ab	Peptides that block human immunodeficiency virus and methods of use thereof
DK0810209T3 (da) *	1992-08-25	2002-08-12	Monsanto Co	Alpha - and beta-aminosyre-hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
US5968942A (en) *	1992-08-25	1999-10-19	G. D. Searle & Co.	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6046190A (en) *	1992-08-25	2000-04-04	G.D. Searle & Co.	Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
US5830897A (en) *	1992-08-27	1998-11-03	G. D. Searle & Co.	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
WO1996005863A1 (fr) *	1994-08-19	1996-02-29	La Region Wallonne	Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation
US5939550A (en) *	1995-06-15	1999-08-17	Pfizer Inc.	Process for preparing derivatives of azabicyclo naphthyridine carboxylic acid comprising a dipeptide
CA2256669A1 (en) *	1996-05-29	1997-12-04	Prototek, Inc.	Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6177404B1 (en) *	1996-10-15	2001-01-23	Merck & Co., Inc.	Conjugates useful in the treatment of benign prostatic hyperplasia
US5783689A (en) *	1996-11-12	1998-07-21	University Of Notre Dame	Antibacterial and antifungal nucleosides
AU4828199A (en) *	1998-06-23	2000-01-10	Board Of Trustees Of The University Of Illinois, The	Multi-drug resistant retroviral protease inhibitors and associated methods
DE19828113A1 (de) *	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US7425541B2 (en) *	1998-12-11	2008-09-16	Medarex, Inc.	Enzyme-cleavable prodrug compounds
US6613879B1 (en) *	1999-05-14	2003-09-02	Boehringer Ingelheim Pharma Kg	FAP-activated anti-tumour compounds
DE60135732D1 (de) *	2000-02-28	2008-10-23	Univ British Columbia	Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
AU2001275525B2 (en) *	2000-06-14	2007-04-26	Medarex, Inc.	Tripeptide prodrug compounds
PT1325910E (pt) *	2000-10-06	2008-10-27	Mitsubishi Tanabe Pharma Corp	Compostos de anel alifático de cinco membros contendo azoto
UA74912C2 (en) *	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003048190A2 (en) *	2001-12-04	2003-06-12	The Curators Of The University Of Missouri	Acyclovir-peptide analogs
AU2003296601A1 (en) *	2002-12-10	2004-06-30	F. Hoffmann-La Roche Ag	Antiviral nucleoside derivatives
CA2515679A1 (en) *	2003-02-21	2004-09-02	Tripep Ab	Glycinamide derivative for inhibiting hiv replication

2003
- 2003-05-08 GB GBGB0310593.9A patent/GB0310593D0/en not_active Ceased
2004
- 2004-05-10 EP EP04731856A patent/EP1620130A1/en not_active Withdrawn
- 2004-05-10 JP JP2006504046A patent/JP2006525235A/ja active Pending
- 2004-05-10 WO PCT/BE2004/000069 patent/WO2004098644A1/en not_active Ceased
- 2004-05-10 AU AU2004236371A patent/AU2004236371B2/en not_active Ceased
- 2004-05-10 CA CA002517338A patent/CA2517338A1/en not_active Abandoned
- 2004-05-10 WO PCT/EP2004/050753 patent/WO2004099135A2/en not_active Ceased
- 2004-05-10 AT AT04741542T patent/ATE375172T1/de not_active IP Right Cessation
- 2004-05-10 DE DE602004009435T patent/DE602004009435T2/de not_active Expired - Fee Related
- 2004-05-10 US US10/555,712 patent/US20080214648A1/en not_active Abandoned
- 2004-05-10 MX MXPA05012019A patent/MXPA05012019A/es active IP Right Grant
- 2004-05-10 US US10/555,930 patent/US8236756B2/en not_active Expired - Fee Related
- 2004-05-10 KR KR1020057017724A patent/KR20060008300A/ko not_active Ceased
- 2004-05-10 NZ NZ543946A patent/NZ543946A/en unknown
- 2004-05-10 ES ES04741542T patent/ES2295879T3/es not_active Expired - Lifetime
- 2004-05-10 BR BRPI0410158-8A patent/BRPI0410158A/pt not_active IP Right Cessation
- 2004-05-10 CN CNA2004800122605A patent/CN1784244A/zh active Pending
- 2004-05-10 PT PT04741542T patent/PT1624897E/pt unknown
- 2004-05-10 AU AU2004235988A patent/AU2004235988A1/en not_active Abandoned
- 2004-05-10 AP AP2005003465A patent/AP2005003465A0/xx unknown
- 2004-05-10 DK DK04741542T patent/DK1624897T3/da active
- 2004-05-10 JP JP2006505596A patent/JP2007526872A/ja not_active Withdrawn
- 2004-05-10 CA CA002525191A patent/CA2525191A1/en not_active Abandoned
- 2004-05-10 EA EA200501768A patent/EA009727B1/ru not_active IP Right Cessation
- 2004-05-10 EP EP04741542A patent/EP1624897B1/en not_active Expired - Lifetime
- 2004-10-05 UA UAA200508359A patent/UA82221C2/uk unknown
2005
- 2005-12-07 ZA ZA200509940A patent/ZA200509940B/en unknown
- 2005-12-08 NO NO20055826A patent/NO20055826L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20070275900A1 (en)	2007-11-29
CA2517338A1 (en)	2004-11-18
NO20055826D0 (no)	2005-12-08
WO2004099135A2 (en)	2004-11-18
EP1624897A2 (en)	2006-02-15
UA82221C2 (uk)	2008-03-25
EP1624897B1 (en)	2007-10-10
MXPA05012019A (es)	2006-02-03
WO2004098644A1 (en)	2004-11-18
CA2525191A1 (en)	2004-11-18
KR20060008300A (ko)	2006-01-26
BRPI0410158A (pt)	2006-05-16
DK1624897T3 (da)	2008-02-11
AU2004236371A1 (en)	2004-11-18
WO2004099135A3 (en)	2005-02-17
CN1784244A (zh)	2006-06-07
AU2004236371B2 (en)	2009-12-17
EA009727B1 (ru)	2008-02-28
US20080214648A1 (en)	2008-09-04
GB0310593D0 (en)	2003-06-11
ATE375172T1 (de)	2007-10-15
US8236756B2 (en)	2012-08-07
JP2007526872A (ja)	2007-09-20
EP1620130A1 (en)	2006-02-01
ZA200509940B (en)	2007-04-25
ES2295879T3 (es)	2008-04-16
AU2004235988A1 (en)	2004-11-18
EA200501768A1 (ru)	2006-04-28
AP2005003465A0 (en)	2005-12-31
JP2006525235A (ja)	2006-11-09
PT1624897E (pt)	2008-01-17
DE602004009435D1 (de)	2007-11-22
NZ543946A (en)	2008-09-26
DE602004009435T2 (de)	2008-07-24

Legal Events

Date	Code	Title	Description
2010-12-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20055826L (no)	2006-02-08	HIV-prodroger spaltbare ved CD26
Murakami et al.	1994	Aeruginosin 298-A, a thrombin and trypsin inhibitor from the blue-green alga Microcystis aeruginosa (NIES-298)
Hu et al.	2005	Synthesis and Structure–activity Relationship of N-alkyl Gly-boro-Pro Inhibitors of DPP4, FAP, and DPP7
TW200407309A (en)	2004-05-16	1,2-Azole derivatives
WO2003002553A3 (en)	2003-03-27	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
NO20030896D0 (no)	2003-02-26	Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler
MXPA03011907A (es)	2004-03-26	Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
WO2003002530A3 (en)	2003-04-03	Pyrrolidines as dipeptidyl peptidase inhibitors
WO1989003223A1 (en)	1989-04-20	Protease inhibitors
IL173802A0 (en)	2006-07-05	Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors
UA99308C2 (ru)	2012-08-10	Аналог азацитидина и его применение
TW200500368A (en)	2005-01-01	Process to tetrahydrotriazolopyrazines and intermediates
TW200615365A (en)	2006-05-16	Azo compound and composition for photo-alignment layer using the same, as well as method for producing photo-alignment layer
US5661167A (en)	1997-08-26	Prolyl endopeptidase inhibitors
Kim et al.	2005	Asymmetric induction in the conjugate addition of thioacetic acid to methacrylamides with chiral auxiliaries
EP1794120A4 (en)	2009-08-26	peptidase
Lin et al.	2003	14‐Membered Cyclopeptides from Paliurus ramosissimus and P. hemsleyanus
Hirata et al.	2011	Facile synthesis of both enantiomers of (pyrrolidin-2-yl) phosphonate from l-proline
DE602006014285D1 (de)	2010-06-24	N-substituierte 3,4-alkylendioxypyrrole, estersubstituierte dihydroxypyrrole und verfahren zur synthese dieser pyrrole
PT1819704E (pt)	2008-10-06	Derivado amida de ácido pirrolopiridina-2-carboxílico útil como inibidor de glicogénio fosforilase
EP1311518B1 (en)	2005-11-02	Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts
WO2007074391A3 (en)	2008-06-26	Preparation of a key intermediate in the synthesis of rosuvastatin
SI1628956T1 (sl)	2011-03-31	Postopek za pripravo spojin z ACE inhibitornim delovanjem
Soroka et al.	2006	Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2, 4-diaminobutanoyl) piperidines
CA3068740A1 (en)	2019-01-31	Synthesis of an azasugar and intermediates thereof